LivingGLP1
Study S000018

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

ClinicalTrials.gov record

Registration

Registration
NCT07547878
Acronym
RAPID-CKD
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
NONE
Status
ENROLLING_BY_INVITATION
Enrollment
64
Start
2026-04-08
Primary completion
2029-03-31
Lead sponsor
Baylor Research Institute
Conditions
Chronic Kidney Disease; Type 2 Diabetes
Interventions
DRUG:Finerenone; DRUG:Semaglutide; DRUG:Lotensin; DRUG:Capoten; DRUG:Enalapril; DRUG:Monopril; DRUG:Lisinopril; DRUG:Univasc; DRUG:Aceon; DRUG:Accupril; DRUG:Altace; DRUG:Mavik; DRUG:Edarbi; DRUG:Atacand; DRUG:Avapro; DRUG:Cozaar; DRUG:Benicar; DRUG:Micardis; DRUG:Diovan; DRUG:Invokana; DRUG:Farxiga; DRUG:Jardiance; DRUG:Ertugliflozin; DRUG:Brenzavvy; DRUG:Sotagliflozin
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • On-study retention rate at 6 months [6 months]
  • Sustained decline in eGFR ≥30% [6 months]
  • Change in UACR [6 months]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0006261Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes.
Rashid AM, Journal of the American Society of Nephrology : JASN
2025Nonrandomized studyPMID 40327845DOIregistry reference BACKGROUND:40327845
R0008088COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Agarwal R, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
2025Randomized trialPMID 39916475DOIregistry reference BACKGROUND:39916475
R0008052Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Neuen BL, Circulation
2024OtherPMID 37952217DOIregistry reference BACKGROUND:37952217
R0008116KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD.
Mottl AK, American journal of kidney diseases : the official journal of the National Kidney Foundation
2024OtherPMID 38142396DOIregistry reference BACKGROUND:38142396
R0019647Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, The New England journal of medicine
2024Randomized trialPMID 38785209DOIregistry reference BACKGROUND:38785209
R0029159Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes.
Khan MS, BMC nephrology
2024Narrative reviewPMID 39090593DOIregistry reference BACKGROUND:39090593
R0008908Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Davies MJ, Diabetes care
2022Narrative reviewPMID 36148880DOIregistry reference BACKGROUND:36148880